Searle’s Daypro (oxaprozin)
Phase IV commitments include two efficacy trials: a placebo- controlled or low-dose controlled study replicating the existing active-control studies of oxaprozin in osteoarthritis; and a fixed-dose trial of oxaprozin doses up to 1,800 mg/day. The studies of the new NSAID, approved on Oct. 29, are to be completed within two years. In addition, FDA has asked the company to complete within two years five studies including: in vitro and in vivo protein binding of oxaprozin; population pharmacokinetics; drug interactions; oxaprozin in patients with renal dysfunction; and multiple-dose, dose-proportionality and pharmacokinetic studies of free and bound oxaprozin in doses ranging from 600- 1,800 mg.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth